
ICON plc: stock overview
Price
$194.65
November 13, 2026Market cap $14.9B
What Ploutos Investor adds for ICON
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
ICON had revenue of $8.2B over the last 12 months and net income of $449M, a net margin of 5.5%. Revenue grew by 24.2% a year on average over the last 5 years. At $194.65 the shares trade at a P/E of 33.2, against a median of 37.0 over the last 4 fiscal years. It has net debt of $2.6B. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $14.9B
- 76.57M shares
- P/E
- 33.2
- Today33.2Median37.0
- Revenue, 12 months
- $8.2B
- +24.2% a year over 5 years
- Net margin
- 5.5%
- 2025: 2.8%, above 46% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+1.2% a year over 2 years
Fiscal years in figures
ICLR's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $16.9B
- $14.9B
- Enterprise value
- $17.5B
- P/E 3-year median: 42.2
- 33.2
- EV / EBIT
- 24.3
- EV / Revenue
- 2.1
- P/B 3-year median: 1.8
- 1.6
- FCF yield 3-year median: 6.2%
- 5.8%
- Earnings yield 3-year median: 2.4%
- 3.0%
Profitability
- Gross margin
- 23.4%
- Operating margin
- 8.7%
- Net margin 3-year median: 6.9%
- 5.5%
- ROIC
- 4.7%
- ROIC, 5-year average
- 4.4%
- ROE
- 4.9%
Growth
- Revenue, yearly change
- +0.8%
- EPS, yearly change
- -67.4%
- FCF, yearly change
- -22.9%
- Revenue, average a year
- +24.2%
- EPS, average a year
- -14.0%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $809M
- Total debt
- $3.5B
- Of which operating leases
- $130M
- Net debt
- $2.6B
- Net debt / EBITDA
- 2.3x
- Interest cover
- 3.8x
- Current ratio
- 1.32
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 5.03%
- Total returned
- 5.03%
- Shares, yearly change
- -5.2%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 87).
Operating margin
5.4%
Above 41% of the 43 companies in its industry, and 51% of all.
Net margin
2.8%
Above 46% of the 42 companies in its industry, and 45% of all.
ROE
2.5%
Above 35% of the 39 companies in its industry, and 37% of all.
ROA
1.4%
Above 38% of the 41 companies in its industry, and 50% of all.
Revenue growth
0.8%
Above 44% of the 40 companies in its industry, and 31% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- ICON PLC
- CIK
- 1060955
- Exchange
- NASDAQ
- Industry (SIC)
- 8731 · Services-Commercial Physical & Biological Research
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 76.57M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ICLR
- JNJJohnson & Johnson+0,00%Compare with ICLR
- ABBVAbbVie+0,00%Compare with ICLR
- UNHUnitedHealth+0,00%Compare with ICLR
- MRKMerck & Company+0,00%Compare with ICLR
- AMGNAmgen+0,00%Compare with ICLR
- TMOThermo Fisher Scientific+0,00%Compare with ICLR
- ABTAbbott Laboratories+0,00%Compare with ICLR
The full analysis
What do ICON's filings show?
These are ICON's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is ICLR's market cap?
ICON plc's market cap is $14.9B, at a price of $194.65 on November 13, 2026 and 76.57M shares.
What is ICLR's P/E?
ICLR's P/E is 33.2, on earnings per share of $5.77 over the last 12 months. The median over the last 4 fiscal years was 37.0.
How much revenue does ICLR have?
ICON had revenue of $8.2B over the last 12 months. Over the last 5 years it changed by +24.2% a year on average.
Does ICLR pay a dividend?
No. ICON paid no regular dividend over the last 12 months.
Where do the figures come from?
From ICON plc's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.